Autopsy report · NCT04521621
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
Cause of deathFunding or business
“Business Reasons”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 9 months before it stopped.
- 76 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Neoplasm Metastasis
- Interventions
- Gebasaxturev; Pembrolizumab
- Participants
- 76
- Sites
- 29
- Countries
- Canada, France, Germany, Hungary, Israel, Italy, Japan, Norway, Peru, Poland, Portugal, Spain and more
Trials that died the same way
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
“Business Reason” - Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
“Financial/Business Reasons” - First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
“Business/Commercial Reasons” - Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
“Organizational reasons” - Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
“For business reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.